We understand that not all labs are alike. NGS applications and content need to be tailored for your lab's needs. A one-size-fits all approach just doesn't work, so we've developed a range of Oncomine Assays to cover the spectrum of panel sizes and purposes. We listen and we create solutions for the way you work.
The Oncomine Precision Assay features carefully curated biomarker content spanning 50 genes based on the latest therapy developments, medical guidelines, and clinical trials.
Enhanced fusion detection provides broad coverage for the most prevalent isoforms, along with novel fusions. You have the option to profile DNA or RNA from FFPE tissue or plasma, giving you a wide range of utility.
All of this is provided with one-day turnaround time and a highly automated workflow on the Genexus System.
The Oncomine Comprehensive Assay, a new version of the original assay with robust performance proven in large clinical oncology trials such as NCI MATCH, is a game changer.
Hematological disorders are complex, heterogeneous diseases with many oncogenic drivers and subtypes. Acute forms of hematological malignancies are very aggressive and can proliferate rapidly. Getting fast, accurate, and meaningful insights is essentail in helping to advance our understanding of these disorders.
Explore our growing portfolio of Oncomine hemato-oncology research assays. Whether you're interested in the assessment of myeloid or lymphoid malignancy samples, we provide the comprehensive suite of tools you need to simplify and expedite your path to answers.
Tumor mutation burden (TMB) is an emerging biomarker that is rapidly gaining traction within the immuno-oncology field. Recent clinical trials have demonstrated that patients with higher TMB are more likely to respond to checkpoint inhibitor therapies, so it will likely become a part of routine clinical biomarker testing in the near future. Studies have shown that NGS is the best technique for detecting TMB. The Oncomine Tumor Mutation Load Assay is the only NGS solution available for use in clinical research laboratories that delivers a TMB assessment in one test workflow with other biomarkers.
See short videos of key opinion leaders talking about their experience with the test and assessing tumor mutation burden in ~2.5 days.
Whether you’re looking at multiple targets or just a few, our NGS solutions combine the power of Ion Torrent technology with cfDNA assays, advanced rare cell isolation, manual or automated cell-free DNA extraction, and digital PCR tools. Together, these solutions enable you to retrospectively assess cancer research samples throughout all stages.
For a complete listing of all available Oncomine assays, please vist thermofisher.com. Find assays for a range of applications:
• Solid tumor profiling from FFPE tissue
• Liquid biopsies
• Hematological malignancy profiling
• Tumor Mutational Burden (TMB) Analysis
For Research Use Only. Not for use in diagnostic procedures.